Safety, Efficacy, PD of FE203799 in Short Bowel Syndrome on Parenteral Support
- Conditions
- Short Bowel Syndrome
- Interventions
- Drug: FE203799 Placebo GLP-2 analogueDrug: FE203799 GLP-2 analogue
- Registration Number
- NCT03415594
- Lead Sponsor
- GlyPharma Therapeutics
- Brief Summary
Part A:once weekly dosing for 4 weeks in patients with short bowel syndrome who require total parenteral nutrition; patients will complete period 1 and after a 6-10 week wash-out, they will enter period 2 (active treatment and placebo); Part B: treatment period 3, is an open label extension to part A and starts after a washout of 6-10 weeks after the last dose in treatment period 2. patients are dosed once weekly for 4 weeks.
- Detailed Description
This trial is divided into 2 parts. Part A of this trial is a repeated dose, placebo controlled, double blind, randomised cross-over trial investigating safety, efficacy and PD of FE 203799 in 8-10 patients with SBS. Additionally, the plasma concentration of FE 203799 will be assessed for determination of the trough and post-dose concentration in SBS patients. The patients will receive a subcutaneous (SC) dose of 5 mg FE 203799 or placebo once weekly for 4 consecutive weeks, and after a washout period of 6-10 weeks, the alternate treatment will be administered once weekly for 4 consecutive weeks. Safety follow-up assessments will be performed 6-10 weeks after the last dose in each treatment period.
Part B of this trial, treatment period 3, is an open label extension to part A that will test a new dose. Following a washout period of 6-10 weeks after the last dose in treatment period 2, the new dose will be administered once weekly for 4 weeks. Safety follow-up assessments will be performed 4-6 weeks after the last dose in treatment period 3.
The first two administrations of trial drug in each treatment period will be performed at the clinic, while the third and fourth dose can be either self-administered by the patient or administered at the clinic if the patient prefers to travel to the site or other considerations make a site visit preferable.
Prior to each administration of trial drug, liver function parameters will be analysed and assessed. During each treatment period, patients who develop extremely high or persistently elevated liver enzymes following trial drug administration will be discontinued from the trial.
The patients will complete a diary during each treatment period with daily data on parenteral support (PS) usage, oral liquid intake at specific periods, trial drug administrations performed at home, local tolerability and adverse events (AEs).
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 8
Not provided
Not provided
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- CROSSOVER
- Arm && Interventions
Group Intervention Description Placebo FE203799 Placebo GLP-2 analogue Placebo FE203799 GLP-2 analogue, once weekly, subcutaneous administration FE203799 5 mg FE203799 GLP-2 analogue FE203799 GLP-2 analogue, once weekly, subcutaneous administration FE203799 10 mg FE203799 GLP-2 analogue FE203799 GLP-2 analogue, once weekly, subcutaneous administration
- Primary Outcome Measures
Name Time Method Incidence of treatment-emergent adverse events Day -28 to Day 29 Adverse events (AEs) as assessed by CTCAE v4.03
- Secondary Outcome Measures
Name Time Method Plasma Trough concentration (Ctrough) of study drug Day 1 - Day 29 Ctrough
Plasma concentration post 72 hours (C72) of study drug Day 1 - Day 29 C72
Assessment of intestinal failure and gut absorption Day -3 and Day 29 Changes from baseline in bone mineral content by DEXA scan
Assessment of gut regeneration Day 1 - Day 29 Measurements of the plasma citrulline (ng/ml)
Trial Locations
- Locations (1)
Rigshospitalet
🇩🇰Copenhagen, Denmark